CN109414514B - Pet成像免疫调节剂 - Google Patents

Pet成像免疫调节剂 Download PDF

Info

Publication number
CN109414514B
CN109414514B CN201780042462.1A CN201780042462A CN109414514B CN 109414514 B CN109414514 B CN 109414514B CN 201780042462 A CN201780042462 A CN 201780042462A CN 109414514 B CN109414514 B CN 109414514B
Authority
CN
China
Prior art keywords
compound
tissue
subject
imaging
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780042462.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN109414514A (zh
Inventor
D·J·唐纳利
K·M·博伊
Y·张
J·金
A·佩纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN109414514A publication Critical patent/CN109414514A/zh
Application granted granted Critical
Publication of CN109414514B publication Critical patent/CN109414514B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/12—Arrangements for detecting or locating foreign bodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201780042462.1A 2016-05-19 2017-05-17 Pet成像免疫调节剂 Active CN109414514B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662338872P 2016-05-19 2016-05-19
US62/338,872 2016-05-19
PCT/US2017/033004 WO2017201111A1 (en) 2016-05-19 2017-05-17 Pet-imaging immunomodulators

Publications (2)

Publication Number Publication Date
CN109414514A CN109414514A (zh) 2019-03-01
CN109414514B true CN109414514B (zh) 2022-03-11

Family

ID=59021563

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780042462.1A Active CN109414514B (zh) 2016-05-19 2017-05-17 Pet成像免疫调节剂

Country Status (25)

Country Link
US (2) US11103605B2 (https=)
EP (2) EP3458111B1 (https=)
JP (1) JP6953444B2 (https=)
KR (1) KR102378288B1 (https=)
CN (1) CN109414514B (https=)
AU (1) AU2017268291B2 (https=)
BR (1) BR112018073642A2 (https=)
CA (1) CA3024844A1 (https=)
CY (1) CY1124241T1 (https=)
DK (1) DK3458111T3 (https=)
EA (1) EA038019B1 (https=)
ES (1) ES2864091T3 (https=)
HR (1) HRP20210644T8 (https=)
HU (1) HUE054306T2 (https=)
IL (1) IL262962B (https=)
LT (1) LT3458111T (https=)
MA (1) MA53402A (https=)
MX (1) MX2018014028A (https=)
PL (1) PL3458111T3 (https=)
PT (1) PT3458111T (https=)
RS (1) RS61742B1 (https=)
SG (1) SG11201810177VA (https=)
SI (1) SI3458111T1 (https=)
SM (1) SMT202100238T1 (https=)
WO (1) WO2017201111A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
US11857352B2 (en) 2016-09-06 2024-01-02 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
EP3548515B1 (en) 2016-12-01 2026-01-21 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
BR112019012986A2 (pt) * 2016-12-23 2019-12-03 Univ Johns Hopkins imageamento de tumores e de células imunes com base na expressão de pd-l1
CA3053348A1 (en) 2017-02-10 2018-08-16 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-lag3 antibodies for immuno-pet imaging
CN110997698B (zh) 2017-06-23 2023-12-26 百时美施贵宝公司 充当pd-1拮抗剂的免疫调节剂
KR102880156B1 (ko) 2017-07-24 2025-11-05 리제너론 파마슈티칼스 인코포레이티드 항cd8 항체 및 이의 용도
US11492375B2 (en) 2017-10-03 2022-11-08 Bristol-Myers Squibb Company Cyclic peptide immunomodulators
CN110504017B (zh) * 2019-07-30 2022-06-10 哈尔滨医科大学 一种示踪剂的制备和使用方法
US11896682B2 (en) 2019-09-16 2024-02-13 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
EP4087857B1 (en) 2020-01-06 2023-11-01 Bristol-Myers Squibb Company Immunomodulators
JP2023517736A (ja) * 2020-03-16 2023-04-26 ブリストル－マイヤーズ スクイブ カンパニー 免疫調節剤
CN115362166A (zh) 2020-03-30 2022-11-18 百时美施贵宝公司 免疫调节剂
US12159403B2 (en) * 2021-06-18 2024-12-03 The United States Government As Represented By The Department Of Veteran Affairs Combination of features from biopsies and scans to predict prognosis in SCLC
CN120500493A (zh) * 2022-12-12 2025-08-15 默沙东有限责任公司 作为颗粒酶b的pet成像剂的环肽

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013010573A1 (en) * 2011-07-18 2013-01-24 Universitaet Muenster Compounds with matrix-metalloproteinase inhibitory activity
CN105209479A (zh) * 2013-03-15 2015-12-30 百时美施贵宝公司 Pd-1/pd-l1和cd80(b7-1)/pd-l1蛋白质/蛋白质相互作用的大环抑制剂

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5128119A (en) 1989-06-12 1992-07-07 Immunomedics, Inc. Methods for technetium/rhenium labeling of f(ab1)2 fragments
US5328679A (en) 1988-04-01 1994-07-12 Immunomedics, Inc. Methods for technetium/rhenium labeling of proteins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
IL113610A0 (en) 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US5746996A (en) 1994-06-03 1998-05-05 Immunomedics, Inc. Thiolation of peptides for radionuclide-based radiodetection and radiotherapy
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5753206A (en) 1995-06-07 1998-05-19 Immunomedics, Inc. Radiometal-binding analogues of luteinizing hormone releasing hormone
AU717020B2 (en) 1996-05-03 2000-03-16 Immunomedics Inc. Targeted combination immunotherapy of cancer
EP0975374B1 (en) 1996-07-12 2007-12-05 Immunomedics, Inc. Radiometal-binding peptide analogues
US6277818B1 (en) 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
US6187284B1 (en) 1997-09-03 2001-02-13 Immunomedics, Inc. Fluorination of proteins and peptides for F-18 positron emission tomography
EP2141175B1 (en) 2007-03-26 2016-07-27 The University of Tokyo Process for synthesizing cyclic peptide compound
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
JP5818237B2 (ja) 2010-09-09 2015-11-18 国立大学法人 東京大学 Ｎ−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法
US10195578B2 (en) 2010-12-03 2019-02-05 The University Of Tokyo Peptide library production method, peptide library, and screening method
CN103732238A (zh) 2011-06-08 2014-04-16 奥瑞基尼探索技术有限公司 用于免疫调节的治疗性化合物
AU2013239366A1 (en) 2012-03-29 2014-10-16 Aurigene Discovery Technologies Limited Immunomodulating cyclic compounds from the BC loop of human PD1
JP6047231B2 (ja) 2012-06-06 2016-12-21 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ β−ヘアピンペプチド模倣薬
JP2013253842A (ja) 2012-06-06 2013-12-19 Univ Of Tokyo ｐＨ依存的に標的分子に結合するペプチドのスクリーニング方法
KR102389677B1 (ko) 2013-03-15 2022-04-21 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
EP3041468B1 (en) 2013-09-06 2018-06-13 Aurigene Discovery Technologies Limited Cyclic peptidomimetic compounds as immunomodulators
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
TN2017000084A1 (en) 2014-09-11 2018-07-04 Bristol Myers Squibb Co Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) * 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
ES2981335T3 (es) * 2014-11-25 2024-10-08 Bristol Myers Squibb Co Novedosos polipéptidos de unión a PD-L1 para obtención de imágenes
MX385081B (es) 2014-11-25 2025-03-14 Bristol Myers Squibb Co Métodos y composiciones para radioetiquetado con 18f de productos biológicos.
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
KR102526034B1 (ko) 2016-11-07 2023-04-25 브리스톨-마이어스 스큅 컴퍼니 면역조정제
CN110997698B (zh) 2017-06-23 2023-12-26 百时美施贵宝公司 充当pd-1拮抗剂的免疫调节剂
US11492375B2 (en) 2017-10-03 2022-11-08 Bristol-Myers Squibb Company Cyclic peptide immunomodulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013010573A1 (en) * 2011-07-18 2013-01-24 Universitaet Muenster Compounds with matrix-metalloproteinase inhibitory activity
CN105209479A (zh) * 2013-03-15 2015-12-30 百时美施贵宝公司 Pd-1/pd-l1和cd80(b7-1)/pd-l1蛋白质/蛋白质相互作用的大环抑制剂

Also Published As

Publication number Publication date
EP3827849A1 (en) 2021-06-02
WO2017201111A1 (en) 2017-11-23
RS61742B1 (sr) 2021-05-31
MX2018014028A (es) 2019-04-04
JP6953444B2 (ja) 2021-10-27
HRP20210644T8 (hr) 2021-06-25
HRP20210644T1 (hr) 2021-05-28
CY1124241T1 (el) 2022-07-22
US20190117801A1 (en) 2019-04-25
US11103605B2 (en) 2021-08-31
BR112018073642A2 (pt) 2019-02-26
AU2017268291B2 (en) 2022-09-29
EA201892635A1 (ru) 2019-04-30
SG11201810177VA (en) 2018-12-28
CA3024844A1 (en) 2017-11-23
DK3458111T3 (da) 2021-04-26
LT3458111T (lt) 2021-05-25
IL262962A (en) 2018-12-31
PT3458111T (pt) 2021-04-09
EP3458111A1 (en) 2019-03-27
AU2017268291A1 (en) 2019-01-17
EP3458111B1 (en) 2021-03-03
JP2019520328A (ja) 2019-07-18
CN109414514A (zh) 2019-03-01
KR102378288B1 (ko) 2022-03-23
SMT202100238T1 (it) 2021-05-07
IL262962B (en) 2020-04-30
EA038019B1 (ru) 2021-06-23
MA53402A (fr) 2021-06-02
HUE054306T2 (hu) 2021-08-30
ES2864091T3 (es) 2021-10-13
US20210386876A1 (en) 2021-12-16
KR20190009330A (ko) 2019-01-28
PL3458111T3 (pl) 2021-06-28
SI3458111T1 (sl) 2021-07-30

Similar Documents

Publication Publication Date Title
CN109414514B (zh) Pet成像免疫调节剂
US20220202966A1 (en) Positron emitting radionuclide labeled peptides for human upar pet imaging
EP3223866B1 (en) Methods and compositions for 18f-radiolabeling of the fibronectin type (iii) domain
EP4537851A1 (en) Trifunctional compound and use thereof
US9433689B2 (en) Probes and methods of imaging non-Hodgkins lymphoma
RS66467B1 (sr) Kompleks koji se sastoji iz jedinjenja koje cilja psma vezano sa radionuklidom olova ili torijuma
JP2021130675A (ja) 放射性核種錯体を調製するための方法およびキット
Zhu et al. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy
Aranda-Lara et al. Improved radiopharmaceutical based on 99mTc-Bombesin–folate for breast tumour imaging
Wen et al. Immuno-SPECT/PET imaging with radioiodinated anti-PD-L1 antibody to evaluate PD-L1 expression in immune-competent murine models and PDX model of lung adenocarcinoma
Prasanphanich et al. The effects of linking substituents on the in vivo behavior of site-directed, peptide-based, diagnostic radiopharmaceuticals
JP2008531988A (ja) 放射性標識ガリウム錯体、その合成法並びに悪性腫瘍におけるｅｇｆｒ発現のｐｅｔイメージングにおける使用
Vangestel et al. In vitro and in vivo evaluation of [99mTc]-labeled tricarbonyl His-annexin A5 as an imaging agent for the detection of phosphatidylserine-expressing cells
US20250135049A1 (en) Methods for Biological Material Labeling and Medical Imaging
CN117813326A (zh) 基于放射的导蛋白-1的检测、伴随测试和治疗方法
Zeglis et al. Radiopharmaceuticals for imaging in oncology with special emphasis on positron-emitting agents
CN103275188B (zh) 放射性标记t140类多肽化合物及其制备方法和应用
Keeling et al. Nuclear Imaging of Inflammation
Lu Development and evaluation of radioimaging agents targeting prostate-specific membrane antigen
Hu et al. Non-invasive HER2 detection in ovarian and breast cancer xenografts with 99m Tc-(HE) 3 Z HER2: V2
Verena Development of bispecific prostate-specific membrane antigen/fibroblast activation protein (PSMA/FAP)-targeting radiotracers for prostate cancer imaging
CN119661694A (zh) 一种靶向mt1-mmp的pet显像剂及其制备方法和应用
Buck et al. Preclinical and clinical tumor imaging with SPECT/CT and PET/CT
BR112017010414B1 (pt) Sondas baseadas em proteína radiomarcada com 18f e composições farmacêuticas

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant